Abstract

Conventional follow-up of teenagers with inflammatory bowel diseases (IBD) is done during scheduled outpatient visits regardless of how well the patient feels. We designed a telemonitoring strategy for early recognition of flares and compared its efficacy with conventional follow-up. Flarometer. Algorithm with advice on treatment and the timing of re-measurement. Multicentre randomised trial in children aged 10–19 years with IBD in clinical remission at baseline. Participants assigned to telemonitoring received automated alerts to complete a symptom score and send a stool sample for calprotectin measurement. This resulted in an individual prediction for flare with associated treatment advice and test interval. In conventional follow-up the health check interval was left to the physician’s discretion. Primary endpoint was cumulative incidence of disease flares. Secondary endpoints were percentage of participants with a positive change in quality-of-life and cost-effectiveness of the intervention. We included 170 participants (84 telemonitoring; 86 conventional follow-up). At 52 weeks the mean number of face-to-face visits was significantly lower in the telemonitoring group compared with conventional follow-up (3.6 vs. 4.3, p < 0.001). The incidence of flares (33 vs. 34%) and the proportion of participants reporting positive change in quality-of-life (56% vs. 46%) were similar. Mean annual cost-saving was €89 and increased to €360 in those compliant to the protocol. Telemonitoring is as safe as conventional follow-up, reduces outpatient visits and societal costs. This strategy is attractive for teenagers and families, and health professionals may be interested in using it to keep teenagers who are well out of hospital and ease pressure on overstretched outpatient services. (Trial registration: NTR3759.)

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.